BIIB is currently up $126 (high was up 180). With 150 million shares that corresponds to being up about 20 billion not 80 (and at high was up $27 billion). I agree AVXL and other AD stocks are undervalued as now there is proof that AD drugs can be approved. Unfortunately, first controlled AVXL AD data won't be out until 3Q2022 at the earliest (4Q2022 Missling time). Therefore major appreciation pf SP in the short term is up to the Rett results.